CENPN and nasopharyngeal carcinoma: Since some chemosynthetic small-molecule drugs could enter the cytoplasm to inhibit BRAF mutation and treated melanoma [50], some small-molecule drugs that can specifically inhibit or degrade CENP-N could be designed to treat nasopharyngeal cancer in the future.